Furiex Pharmaceuticals Announces First Quarter 2013 Earnings Release and Conference Call

  Furiex Pharmaceuticals Announces First Quarter 2013 Earnings Release and
  Conference Call

Business Wire

MORRISVILLE, N.C. -- April 09, 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its first quarter
2013 financial results on Tuesday, May 7, 2013, after the market closes. The
earnings news release will be available on the Furiex website at
www.furiex.com.

On Wednesday, May 8, 2013, at 9 a.m. ET, Furiex will conduct a live conference
call and audio webcast to discuss financial results and product portfolio. A
Q&A session will follow. The conference call will be broadcast live over the
Internet and will also be available using the following direct dial numbers:

Participant dial-in:     +1 877 677 9122 (U.S./Canada)
                             +1 708 290 1401 (International)
Conference ID:               34626629

All interested parties can access the webcast through the Presentations &
Events link in the Investors section of the Furiex website at www.furiex.com.
The webcast will be archived shortly after the call for on-demand replay.

About Furiex

Furiex Pharmaceuticals is a drug development collaboration company that uses
innovative clinical development design to accelerate and increase value of
drug development programs by advancing them through the drug discovery and
development process in a cost-efficient manner. Our drug development programs
are designed and driven by a core team with extensive drug development
experience. The company collaborates with pharmaceutical and biotechnology
companies and has a strong, diversified product portfolio and pipeline with
multiple therapeutic candidates, including one Phase III-ready asset, two
compounds in Phase III development, one of which is with a partner, three
products on the market and a fourth approved in the United States but not yet
launched. The company's mission is to develop innovative medicines faster and
at a lower cost, thereby improving profitability and accelerating time to
market while providing life-improving therapies for patients. For more
information, visit www.furiex.com.

Contact:

Furiex Pharmaceuticals, Inc.
Media/Analysts/Investors:
Sailash Patel, 919-456-7814
sailash.patel@furiex.com
 
Press spacebar to pause and continue. Press esc to stop.